LENSAR (LNSR) Stock Price, News & Analysis

Company Overview

LENSAR, Inc., headquartered in Orlando, Florida, is a medical technology company specializing in advanced laser systems for ophthalmic surgery. Its flagship product, the LENSAR Laser System, combines proprietary three-dimensional imaging with precision-guided femtosecond laser delivery to perform critical steps in cataract procedures, including capsulotomy creation, lens fragmentation and corneal incisions.

Founded in 2005, LENSAR has concentrated its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment. The company holds multiple patents related to its image-guided treatment planning and laser control algorithms. Clinical collaborations and peer-reviewed studies have supported the safety and efficacy of the LENSAR system, demonstrating improvements in procedural consistency and efficiency.

Operating across North America, Europe, the Asia-Pacific region and Latin America, LENSAR markets its laser platforms to hospitals, ambulatory surgery centers and specialty eye clinics. The company offers comprehensive training programs for ophthalmic surgeons, ongoing technical support and regular software upgrades to help practices integrate femtosecond laser technology. By maintaining a focused portfolio of ophthalmic solutions, LENSAR seeks to advance the standard of care in cataract surgery through continuous innovation and service excellence.

Key Stats

• Today's Range: $12.30 to $12.51
• 50-Day Range: $12.04 to $13.32
• 52-Week Range: $3.80 to $17.31
• Volume: 21,117 shs
• Average Volume: 124,180 shs
• Market Capitalization: $147.34 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Hold

LENSAR Stock Analysis - MarketRank™

LENSAR scored higher than 32% of companies evaluated by MarketBeat, and ranked 825th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.7 / 5
• Analyst Rating: Hold

Consensus Rating

LENSAR has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

LENSAR has a consensus price target of $15.00, representing about 21.8% upside from its current price of $12.32.

Amount of Analyst Coverage

LENSAR has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of LENSAR is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of LENSAR is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

LENSAR has a P/B Ratio of 29.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.51% of the float of LENSAR has been sold short.

Short Interest Ratio / Days to Cover

LENSAR has a short interest ratio ("days to cover") of 6.7.

Change versus previous month

Short interest in LENSAR has recently increased by 0.87%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

LENSAR does not currently pay a dividend.

Dividend Growth

LENSAR does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.51% of the float of LENSAR has been sold short.

Short Interest Ratio / Days to Cover

LENSAR has a short interest ratio ("days to cover") of 6.7.

Change versus previous month

Short interest in LENSAR has recently increased by 0.87%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 1.83

News Sentiment

LENSAR has a news sentiment score of 1.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.94 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for LENSAR this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added LENSAR to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, LENSAR insiders have not sold or bought any company stock.

Percentage Held by Insiders

66.00% of the stock of LENSAR is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

40.15% of the stock of LENSAR is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LNSR Stock Analysis - Frequently Asked Questions

How have LNSR shares performed this year?

LENSAR's stock was trading at $8.94 at the beginning of 2025. Since then, LNSR stock has increased by 37.8% and is now trading at $12.3150.

How were LENSAR's earnings last quarter?

LENSAR, Inc. (NASDAQ:LNSR) announced its quarterly earnings data on Thursday, August, 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.08. The business earned $11.36 million during the quarter, compared to analysts' expectations of $16.55 million. LENSAR had a negative trailing twelve-month return on equity of 737.30% and a negative net margin of 84.49%.

Who are LENSAR's major shareholders?

LENSAR's top institutional investors include Brandes Investment Partners LP (4.72%), Groupe la Francaise (2.11%), Geode Capital Management LLC (1.86%) and Credit Industriel ET Commercial (1.43%). Insiders that own company stock include Thomas R Staab II and Gary M Winer.
View institutional ownership trends.

How do I buy shares of LENSAR?

Shares of LNSR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of LENSAR own?

Based on aggregate information from My MarketBeat watchlists, some other companies that LENSAR investors own include Arch Capital Group (ACGL), Aprea Therapeutics (APRE), Artelo Biosciences (ARTL), AstraZeneca (AZN), Baidu (BIDU), Cidara Therapeutics (CDTX) and Carlyle Group (CG).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/15/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:LNSR
• CIK: 1320350
• Web: www.lensar.com
• Phone: 888-536-7271
• Fax: N/A
• Employees: 110
• Year Founded: N/A

Price Target and Rating

• Average Price Target for LENSAR: $15.00
• High Price Target: $15.00
• Low Price Target: $15.00
• Potential Upside/Downside: +20.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$31.40 million
• Net Margins: -84.49%
• Pretax Margin: -84.49%
• Return on Equity: -737.30%
• Return on Assets: -72.60%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.52
• Quick Ratio: 0.88

Sales & Book Value

• Annual Sales: $53.49 million
• Price / Sales: 2.77
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.42 per share
• Price / Book: 29.56

Miscellaneous

• Outstanding Shares: 11,940,000
• Free Float: 4,058,000
• Market Cap: $148.25 million
• Optionable: Optionable
• Beta: 0.49